David is an operating partner at Foresite Labs, and also serves as senior advisor at Foresite Capital. With more than 20 years of expertise in clinical development, drug commercialization and advancing therapies for patients in need, David supports Foresite Labs’ incubated companies, particularly their translational and clinical research commitments, and explores and initiates new programs and company concepts.
David joined Foresite Labs from Regeneron, where he was the executive vice president and head of global clinical development. During his tenure with the company, David managed programs across different therapeutic focus areas, including its successful Dupixent program and its COVID therapeutic antibody. Prior to Regeneron, he was the head of global development for specialty medicine at Bayer Pharmaceuticals and previously served as executive director and global product area leader (Angiogenesis) at Amgen.
